ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $171,964 | -37.1% | 175,473 | -10.8% | 0.00% | – |
| Q2 2023 | $273,362 | +13.9% | 196,663 | +30.3% | 0.00% | – |
| Q1 2023 | $239,968 | -44.4% | 150,923 | +117.8% | 0.00% | -100.0% |
| Q4 2022 | $431,795 | -99.8% | 69,309 | +135.7% | 0.00% | – |
| Q3 2022 | $197,040,000 | +27.9% | 29,409 | +21.4% | 0.00% | – |
| Q2 2022 | $154,084,000 | +646.6% | 24,227 | +444.7% | 0.00% | – |
| Q1 2022 | $20,639,000 | -28.9% | 4,448 | -23.3% | 0.00% | – |
| Q4 2021 | $29,010,000 | -99.1% | 5,802 | -97.7% | 0.00% | -100.0% |
| Q3 2021 | $3,070,027,000 | +14130.9% | 254,774 | +24877.8% | 0.00% | – |
| Q2 2021 | $21,573,000 | -74.5% | 1,020 | -66.2% | 0.00% | – |
| Q1 2021 | $84,627,000 | +10.2% | 3,017 | +2.1% | 0.00% | – |
| Q4 2020 | $76,804,000 | -96.9% | 2,954 | -95.5% | 0.00% | -100.0% |
| Q3 2020 | $2,454,707,000 | +975.6% | 66,040 | +1384.7% | 0.00% | – |
| Q2 2020 | $228,227,000 | -47.3% | 4,448 | -67.6% | 0.00% | -100.0% |
| Q1 2020 | $432,812,000 | -89.2% | 13,727 | -79.6% | 0.00% | -85.7% |
| Q4 2019 | $4,020,612,000 | +2612.7% | 67,426 | +1567.7% | 0.01% | – |
| Q3 2019 | $148,216,000 | +11.4% | 4,043 | +41.3% | 0.00% | – |
| Q2 2019 | $133,094,000 | -34.3% | 2,861 | -43.3% | 0.00% | – |
| Q1 2019 | $202,557,000 | +238.7% | 5,045 | +288.1% | 0.00% | – |
| Q4 2018 | $59,800,000 | -19.4% | 1,300 | -22.3% | 0.00% | – |
| Q3 2018 | $74,231,000 | +19.0% | 1,673 | +5.1% | 0.00% | – |
| Q2 2018 | $62,390,000 | -96.6% | 1,592 | -93.8% | 0.00% | -100.0% |
| Q1 2018 | $1,861,051,000 | +685.4% | 25,730 | +614.9% | 0.00% | – |
| Q4 2017 | $236,958,000 | -97.7% | 3,599 | -98.2% | 0.00% | -100.0% |
| Q3 2017 | $10,097,977,000 | +13657.5% | 201,476 | +12603.4% | 0.02% | – |
| Q2 2017 | $73,400,000 | +2599.5% | 1,586 | +1959.7% | 0.00% | – |
| Q1 2017 | $2,719,000 | -10.6% | 77 | -68.3% | 0.00% | – |
| Q4 2016 | $3,042,000 | -77.4% | 243 | -75.0% | 0.00% | – |
| Q3 2016 | $13,462,000 | +141.2% | 972 | +72.0% | 0.00% | – |
| Q2 2016 | $5,582,000 | -93.4% | 565 | -85.2% | 0.00% | – |
| Q4 2015 | $84,944,000 | +26.1% | 3,816 | +33.7% | 0.00% | – |
| Q3 2015 | $67,349,000 | -96.2% | 2,855 | -87.0% | 0.00% | -100.0% |
| Q2 2015 | $1,789,072,000 | +13224.4% | 21,882 | +14991.0% | 0.01% | – |
| Q1 2015 | $13,427,000 | +32.3% | 145 | -65.1% | 0.00% | – |
| Q3 2014 | $10,151,000 | +134.8% | 415 | +52.0% | 0.00% | – |
| Q2 2014 | $4,324,000 | +1466.7% | 273 | +1265.0% | 0.00% | – |
| Q1 2014 | $276,000 | +67.3% | 20 | +66.7% | 0.00% | – |
| Q4 2013 | $165,000 | – | 12 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |